On Wednesday, BMO Capital maintained its Outperform rating and $70.00 price target for Intellia Therapeutics (NASDAQ:), a company specializing in…
Read More »On Wednesday, BMO Capital maintained its Outperform rating and $70.00 price target for Intellia Therapeutics (NASDAQ:), a company specializing in…
Read More »